

Provide accurate medication guidance
on targeted therapy for patients
with Non-Small Cell Lung Cancer

SENTISTM Lung Cancer Medication Guidance

SENTISTM Lung Cancer Medication Guidance can provide informed treatment decisions for advanced non-small cell lung cancer patients and identify treatment options or clinical trials for patients before starting first-line therapy or during the disease progression.

Gene List (50 genes)

- Genes from NCCN guidelines recommended

ALK	BRAF	EGFR	ERBB2	KRAS	MET	NTRK1	NTRK3	RET	ROS1
-----	------	------	-------	------	-----	-------	-------	-----	------

- Genes from clinical trials recommended

AKT1	CDKN2A	DDR2	FBXW7	FGFR1	FGFR3	HRAS	KDR	MAPK1	NF1	NFE2L2
NRAS	PIK3CA	PTEN	STK11	TP53	VEGFA					

Genes associated with the development of Non-Small Cell Lung Cancer

APC	ARID1B	ATM	BCL2L11	CHEK2	CTNNB1	EPHA3	EPHA5	ERBB4	FGFR2	FGFR4
IGF1R	KIT	KEAP1	MAP2K1	MST1R	NOTCH1	PDGFRA	PTPRD	RB1	SMAD4	TOP1
U2AF1										

☒ Genes for CNV detection

☒ Fusion genes

All the genes can be detected for single-nucleotide variants (SNVs) and Insertion and deletion variants (Indels)

Sample Type

Fresh tumor tissue, FFPE sections.

Information

Product Code	HW 2227
Product Name	SENTISTM Lung Cancer Medication Guidance
Turnaround Time	11 Weekdays*
Sequencing Depth*	> 500X
DNA Input	≥ 100ng

* The time period from the arrival of the sample in Hong Kong to the issuance of the report in Tianjin.

* Sequencing depth that removes duplicates and low-quality sequences.

Advantages



Accurate
Stable detection of low-frequency variants as low as 1%.



Authoritative
This kit has obtained CE and NMPA certifications. The laboratory has passed quality management system certifications such as ISO 9001 and ISO 15189, and has passed quality assessments more than 1,700 times.

Drugs List for Non-Small Cell Lung Cancer

Capivasertib	TQ-B3139	Dabrafenib	Nivolumab	SHR-1701	Alflutinib	Necitumumab
Selumetinib	Glesatinib	Gefitinib	Entrectinib	Osimertinib	Infigratinib	Atezolizumab
ARX788	Temsirolimus	Trametinib	Sym015	Brigatinib	Anlotinib	Palbociclib
Afatinib + Selumetinib	Brigatinib + Cetuximab	Pyrotinib + Apatinib	Dasatinib + Erlotinib	Osimertinib + Anlotinib	Neratinib + Temsirolimus	Afatinib + Cetuximab
Abemaciclib	Mobocertinib	Rociletinib	Poziotinib	AMG 337	AZD4547	RO4987655
Ceritinib	Aumolertinib	Lifirafenib	Dovitinib	WZ4002	Neratinib	Pyrotinib
CLN-081	Onartuzumab	Alectinib	Sotorasib	Icotinib	Rocelitinib	Crizotinib
A166	Naquotinib	ASP3026	LNP3794	Ensartinib	Ulixertinib	Nazartinib
Olmutinib	Lapatinib	Afatinib + Apatinib	Sapanisertib	Capmatinib	Larotrectinib	Lorlatinib
Erlotinib + Bevacizumab	Dabrafenib + Trametinib	Osimertinib + Necitumumab	Osimertinib + Gefitinib	Ado-trastuzumab emtansine (T-DM1)	Pembrolizumab	Tepotinib
Afatinib	Vemurafenib	Dacomitinib	Oleclumab	Avitinib	Cetuximab	Savolitinib
Selpercatinib	Taselisib	Erlotinib	Sorafenib	AZD3759	Lazertinib	Adavosertib
Vandetanib	Bortezomib	Cabozantinib	Buparlisib	AZD8186	Sirolimus	Everolimus
Zeteletinib	Pralsetinib	Lenvatinib	Sunitinib	Nintedanib	Taletrectinib	Repotrectinib
Trastuzumab	Tesevatinib	Bevacizumab	DZD9008	Dasatinib	Imatinib	Adagrasib
Trastuzumab + Lapatinib	Amivantamab -vmjw	Fam-trastuzumab deruxtecan-nxki	Icotinib + Anlotinib	Erlotinib + Ramucirumab	Osimertinib + Savolitinib	Oleclumab + Durvalumab

www.bgi.com/global/
info@bgi.com



For a complete listing of our global offices, please visit www.bgi.com/global/.
Copyright ©2024 BGI. All rights reserved. The BGI logo and SENTIS logo are trademarks of BGI. All trademarks are the property of BGI, or their respective owners.
Information, descriptions and specifications in this publication are subject to change without notice.
Published January 2024.
Unless otherwise informed, certain sequencers and sequencing reagents are not available in selected countries or regions. Please contact a representative for regional availability.
The company reserves the right to the final interpretation.

